157 related articles for article (PubMed ID: 22385684)
1. [Skin manifestations of new targeted treatments].
Hello M; Barbarot S; Connault J
Rev Med Interne; 2012 May; 33(5):273-8. PubMed ID: 22385684
[TBL] [Abstract][Full Text] [Related]
2. Skin Manifestations of Targeted Antineoplastic Therapy.
Sanmartín O
Curr Probl Dermatol; 2018; 53():93-104. PubMed ID: 29131041
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
[TBL] [Abstract][Full Text] [Related]
4. [Dermatological side effects of epidermal growth factor receptor inhibitors].
Doebelin B; Ly A; Allombert C; Faure M; Claudy A
Presse Med; 2008 Mar; 37(3 Pt 2):485-9. PubMed ID: 17601698
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: Part II. Targeted therapy.
Reyes-Habito CM; Roh EK
J Am Acad Dermatol; 2014 Aug; 71(2):217.e1-217.e11; quiz 227-8. PubMed ID: 25037801
[TBL] [Abstract][Full Text] [Related]
6. [Dermatologic adverse events of the new targeted anticancer therapies used in oncodermatology].
Sibaud V; Delord JP; Chevreau C; Gangloff D; Garrido-Stowhas I
Ann Chir Plast Esthet; 2012 Apr; 57(2):106-13. PubMed ID: 22425393
[TBL] [Abstract][Full Text] [Related]
7. [Cutaneous side effects of medical tumor therapy].
Degen A; Alter M; Schenck F; Kapp A; Gutzmer R
Hautarzt; 2011 Jun; 62(6):444-50. PubMed ID: 21503784
[TBL] [Abstract][Full Text] [Related]
8. Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments.
Seneschal J; Milpied B; Vergier B; Lepreux S; Schaeverbeke T; Taïeb A
Br J Dermatol; 2009 Nov; 161(5):1081-8. PubMed ID: 19681863
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous reactions to epidermal growth factor receptor inhibitors.
Pomerantz RG; Mirvish ED; Geskin LJ
J Drugs Dermatol; 2010 Oct; 9(10):1229-34. PubMed ID: 20941947
[TBL] [Abstract][Full Text] [Related]
10. New drug therapies and their effect on the skin.
Treudler R
J Dtsch Dermatol Ges; 2009 Jul; 7(7):623-37. PubMed ID: 19614812
[TBL] [Abstract][Full Text] [Related]
11. Fixed drug eruption related to sunitinib: a case report.
Bhatia A; Jha N; Kanish B
Dermatol Online J; 2018 Jun; 24(6):. PubMed ID: 30142719
[TBL] [Abstract][Full Text] [Related]
12. Adverse cutaneous reactions to the new second-generation tyrosine kinase inhibitors (dasatinib, nilotinib) in chronic myeloid leukemia.
Delgado L; Giraudier S; Ortonne N; Zehou O; Cordonnier C; Hulin A; Chosidow O; Tulliez M; Valeyrie-Allanore L
J Am Acad Dermatol; 2013 Nov; 69(5):839-840. PubMed ID: 24124828
[No Abstract] [Full Text] [Related]
13. Pattern and Severity of Psoriasiform Eruptions in Patients with Inflammatory Bowel Diseases, Arthritis or Skin Inflammatory Disorders Treated with TNF-alpha Inhibitors.
Darrigade AS; Milpied B; Truchetet ME; Schaeverbeke T; Laharie D; Zerbib F; Beylot-Barry M; Jouary T; Taïeb A; Ezzedine K; Seneschal J
Acta Derm Venereol; 2017 Jun; 97(6):731-734. PubMed ID: 28218339
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
[TBL] [Abstract][Full Text] [Related]
15. Predictors of Tumor Response to Cetuximab and Panitumumab in 116 Patients and a Review of Approaches to Managing Skin Toxicity.
Jaka A; Gutiérrez-Rivera A; López-Pestaña A; del Alcázar E; Zubizarreta J; Vildosola S; Arregui MA; Sarasqueta C; Lobo C; Tuneu A
Actas Dermosifiliogr; 2015; 106(6):483-92. PubMed ID: 25798804
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancer.
Kubo A; Hashimoto H; Takahashi N; Yamada Y
World J Gastroenterol; 2016 Jan; 22(2):887-94. PubMed ID: 26811634
[TBL] [Abstract][Full Text] [Related]
17. Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.
Wu PA; Balagula Y; Lacouture ME; Anadkat MJ
Curr Opin Oncol; 2011 Jul; 23(4):343-51. PubMed ID: 21537180
[TBL] [Abstract][Full Text] [Related]
18. [Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors].
Deslandres M; Sibaud V; Chevreau C; Delord JP
Ann Dermatol Venereol; 2008 Jan; Spec No 1():16-24. PubMed ID: 18342113
[TBL] [Abstract][Full Text] [Related]
19. Kinase inhibitor-induced pustules.
Laffitte E; Saurat JH
Dermatology; 2005; 211(4):305-6. PubMed ID: 16286735
[No Abstract] [Full Text] [Related]
20. [New tyrosine kinase and EGFR inhibitors in cancer therapy. Cardiac and skin toxicity as relevant side effects. Part B: Skin].
Ehmann LM; Heinemann V; Wollenberg A
Internist (Berl); 2011 Nov; 52(11):1359-64. PubMed ID: 21796420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
